212 related articles for article (PubMed ID: 25047949)
1. Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase.
Guillen KP; Kurkjian C; Harrison RG
J Biomed Sci; 2014 Jul; 21(1):65. PubMed ID: 25047949
[TBL] [Abstract][Full Text] [Related]
2. Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Guillen KP; Restuccia A; Kurkjian C; Harrison RG
Pancreas; 2015 Aug; 44(6):945-52. PubMed ID: 25899647
[TBL] [Abstract][Full Text] [Related]
3. Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.
Krais JJ; De Crescenzo O; Harrison RG
PLoS One; 2013; 8(10):e76403. PubMed ID: 24098491
[TBL] [Abstract][Full Text] [Related]
4. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer.
Martiniello-Wilks R; Wang XY; Voeks DJ; Dane A; Shaw JM; Mortensen E; Both GW; Russell PJ
J Gene Med; 2004 Dec; 6(12):1343-57. PubMed ID: 15493036
[TBL] [Abstract][Full Text] [Related]
5. Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine.
Van Rite BD; Harrison RG
Cancer Lett; 2011 Aug; 307(1):53-61. PubMed ID: 21546157
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.
Sorscher EJ; Hong JS; Allan PW; Waud WR; Parker WB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):321-9. PubMed ID: 22760227
[TBL] [Abstract][Full Text] [Related]
7. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
[TBL] [Abstract][Full Text] [Related]
8. Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
Kazlauskas A; Darinskas A; Meškys R; Tamašauskas A; Urbonavičius J
BMC Cancer; 2019 Mar; 19(1):197. PubMed ID: 30832616
[TBL] [Abstract][Full Text] [Related]
9. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease.
Martiniello-Wilks R; Dane A; Voeks DJ; Jeyakumar G; Mortensen E; Shaw JM; Wang XY; Both GW; Russell PJ
J Gene Med; 2004 Jan; 6(1):43-54. PubMed ID: 14716676
[TBL] [Abstract][Full Text] [Related]
10. Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.
Singh PP; Joshi S; Russell PJ; Nair S; Khatri A
BMC Cancer; 2011 Aug; 11():368. PubMed ID: 21861932
[TBL] [Abstract][Full Text] [Related]
11. Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer.
Singh PP; Joshi S; Russell PJ; Verma ND; Wang X; Khatri A
Clin Cancer Res; 2011 Jun; 17(12):4006-18. PubMed ID: 21531822
[TBL] [Abstract][Full Text] [Related]
12. Prodrug converting enzyme gene delivery by L. monocytogenes.
Stritzker J; Pilgrim S; Szalay AA; Goebel W
BMC Cancer; 2008 Apr; 8():94. PubMed ID: 18402662
[TBL] [Abstract][Full Text] [Related]
13. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line.
Trinh QT; Austin EA; Murray DM; Knick VC; Huber BE
Cancer Res; 1995 Nov; 55(21):4808-12. PubMed ID: 7585511
[TBL] [Abstract][Full Text] [Related]
14. Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells.
Palwai NR; Zang XP; Harrison RG; Pento JT
Anticancer Res; 2007; 27(5A):3435-9. PubMed ID: 17970092
[TBL] [Abstract][Full Text] [Related]
15. Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature.
Van Rite BD; Lazrak YA; Pagnon ML; Palwai NR; Neves LF; McFetridge PS; Harrison RG
Cancer Lett; 2011 Feb; 301(2):177-84. PubMed ID: 21194833
[TBL] [Abstract][Full Text] [Related]
16. Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.
Tai CK; Wang W; Lai YH; Logg CR; Parker WB; Li YF; Hong JS; Sorscher EJ; Chen TC; Kasahara N
Cancer Gene Ther; 2010 Sep; 17(9):614-23. PubMed ID: 20467451
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to irradiation.
Anello R; Cohen S; Atkinson G; Hall SJ
J Urol; 2000 Dec; 164(6):2173-7. PubMed ID: 11061950
[TBL] [Abstract][Full Text] [Related]
18. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.
Pederson LC; Buchsbaum DJ; Vickers SM; Kancharla SR; Mayo MS; Curiel DT; Stackhouse MA
Cancer Res; 1997 Oct; 57(19):4325-32. PubMed ID: 9331094
[TBL] [Abstract][Full Text] [Related]
19. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase.
Parker WB; King SA; Allan PW; Bennett LL; Secrist JA; Montgomery JA; Gilbert KS; Waud WR; Wells AH; Gillespie GY; Sorscher EJ
Hum Gene Ther; 1997 Sep; 8(14):1637-44. PubMed ID: 9322865
[TBL] [Abstract][Full Text] [Related]
20. Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide.
Krais JJ; Virani N; McKernan PH; Nguyen Q; Fung KM; Sikavitsas VI; Kurkjian C; Harrison RG
Mol Cancer Ther; 2017 Sep; 16(9):1855-1865. PubMed ID: 28522586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]